skip to content
Terbutaline pump for the prevention of preterm birth Preview this item
ClosePreview this item
Checking...

Terbutaline pump for the prevention of preterm birth

Author: Laura Gaudet; United States. Agency for Healthcare Research and Quality.; University of Ottawa Evidence-based Practice Center.
Publisher: Rockville, MD : Agency for Healthcare Research and Quality, [2011]
Series: Comparative effectiveness review, no. 35.; AHRQ publication, no. 11-EHC068-EF.
Edition/Format:   eBook : Document : National government publication : English
Summary:
BACKGROUND: Tocolytic agents inhibit contractions during the labor process. Subcutaneous terbutaline (SQ terbutaline) infusion by pump is used as a prolonged (beyond 48-72 hours) maintenance tocolytic following acute treatment of preterm contractions. The effectiveness and safety of this maintenance tocolysis have not been clearly established. OBJECTIVES: To compare the benefits and harms of the SQ terbutaline pump  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Evaluation Studies
Meta-Analysis
Tables
Material Type: Document, Government publication, National government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Laura Gaudet; United States. Agency for Healthcare Research and Quality.; University of Ottawa Evidence-based Practice Center.
OCLC Number: 793411708
Notes: "September 2011."
"Contract No. HHSA 290 2007 10059 I."
Description: 1 online resource (PDF file (various pagings)) : illustrations.
Series Title: Comparative effectiveness review, no. 35.; AHRQ publication, no. 11-EHC068-EF.
Responsibility: prepared for, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by, University of Ottawa Evidence-based Practice Center ; investigators, Laura Gaudet [and others].

Abstract:

BACKGROUND: Tocolytic agents inhibit contractions during the labor process. Subcutaneous terbutaline (SQ terbutaline) infusion by pump is used as a prolonged (beyond 48-72 hours) maintenance tocolytic following acute treatment of preterm contractions. The effectiveness and safety of this maintenance tocolysis have not been clearly established. OBJECTIVES: To compare the benefits and harms of the SQ terbutaline pump with other tocolytics, conservative management, or placebo in specific populations of women with arrested preterm labor, and to explore confounding by level of maternal activity and care. DATA SOURCES: MEDLINE (1950 to April 1, 2011); Embase (1980 to April 1, 2011); CINAHL (1985 to December 7, 2009), the Cochrane Library (April 1, 2011), and the Centre for Reviews and Dissemination databases (January 2, 2010). We also reviewed grey literature. REVIEW METHODS: We followed a prior systematic review protocol. Two reviewers independently included reports that investigated SQ terbutaline pump therapy in women between 24-36 weeks' gestation following arrest of preterm labor. We included noncomparative studies only for pump-related harms. Non-English records without an English abstract were excluded. We also excluded case reports but sought Food and Drug Administration (FDA) summaries of postmarketing surveillance data. One reviewer extracted data into a standardized electronic form and assessed study risk of bias and applicability. A second reviewer verified data. RESULTS: Two randomized trials, one nonrandomized trial, and 11 observational studies met inclusion criteria. In women with recurrent preterm labor (RPTL) and singleton gestation, the strength of evidence favoring the SQ terbutaline pump over oral tocolytics or no treatment is low for the outcomes of incidence of delivery at <32 weeks and <37 weeks, and mean days of pregnancy prolongation. In women with RPTL and twin gestation, the strength of evidence favoring the pump over oral tocolytics is low for neonatal death, incidence of delivery at <32 weeks, and mean days of pregnancy prolongation. Strength of evidence is insufficient for bronchopulmonary dysplasia, incidence of delivery <28 weeks and <34 weeks, and withdrawals due to adverse events. Observational studies of medium to high risk of bias showed the benefit of the SQ terbutaline pump for other surrogate outcomes, such as birth weight and neonatal intensive care unit (NICU) admission. Absent or inconclusive evidence addressed all other neonatal health outcomes, neonatal harms, maternal harms, and pump-related outcomes. An assessment of confounding by maternal activity and maternal care was not possible due to sparse data. Until 2009, several cases of maternal deaths and maternal cardiovascular events in association with terbutaline tocolysis have been reported to the FDA. CONCLUSIONS: The evidence base consists of a small number of biased studies. A substantial body of evidence originated from one proprietary database. Although evidence suggests that pump therapy is beneficial as maintenance tocolysis, our confidence in its validity and reproducibility is low. While postmarketing surveillance has detected cases of serious harms, safety of the therapy remains unclear.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/793411708> # Terbutaline pump for the prevention of preterm birth
    a schema:MediaObject, schema:Book, schema:CreativeWork ;
   library:oclcnum "793411708" ;
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/mdu> ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/1107750807#Place/rockville_md> ; # Rockville, MD
   schema:about <http://experiment.worldcat.org/entity/work/data/1107750807#Topic/terbutaline_therapeutic_use> ; # Terbutaline--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/1107750807#Topic/infusion_pumps> ; # Infusion Pumps
   schema:about <http://experiment.worldcat.org/entity/work/data/1107750807#Topic/tocolytic_agents_therapeutic_use> ; # Tocolytic Agents--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/1107750807#Topic/obstetric_labor_premature_prevention_&_control> ; # Obstetric Labor, Premature--prevention & control
   schema:about <http://experiment.worldcat.org/entity/work/data/1107750807#Topic/terbutaline_adverse_effects> ; # Terbutaline--adverse effects
   schema:bookFormat schema:EBook ;
   schema:contributor <http://viaf.org/viaf/5649149919442706650003> ; # University of Ottawa Evidence-based Practice Center.
   schema:contributor <http://viaf.org/viaf/129508251> ; # United States. Agency for Healthcare Research and Quality.
   schema:contributor <http://viaf.org/viaf/250176625> ; # Laura Gaudet
   schema:datePublished "2011" ;
   schema:description "BACKGROUND: Tocolytic agents inhibit contractions during the labor process. Subcutaneous terbutaline (SQ terbutaline) infusion by pump is used as a prolonged (beyond 48-72 hours) maintenance tocolytic following acute treatment of preterm contractions. The effectiveness and safety of this maintenance tocolysis have not been clearly established. OBJECTIVES: To compare the benefits and harms of the SQ terbutaline pump with other tocolytics, conservative management, or placebo in specific populations of women with arrested preterm labor, and to explore confounding by level of maternal activity and care. DATA SOURCES: MEDLINE (1950 to April 1, 2011); Embase (1980 to April 1, 2011); CINAHL (1985 to December 7, 2009), the Cochrane Library (April 1, 2011), and the Centre for Reviews and Dissemination databases (January 2, 2010). We also reviewed grey literature. REVIEW METHODS: We followed a prior systematic review protocol. Two reviewers independently included reports that investigated SQ terbutaline pump therapy in women between 24-36 weeks' gestation following arrest of preterm labor. We included noncomparative studies only for pump-related harms. Non-English records without an English abstract were excluded. We also excluded case reports but sought Food and Drug Administration (FDA) summaries of postmarketing surveillance data. One reviewer extracted data into a standardized electronic form and assessed study risk of bias and applicability. A second reviewer verified data. RESULTS: Two randomized trials, one nonrandomized trial, and 11 observational studies met inclusion criteria. In women with recurrent preterm labor (RPTL) and singleton gestation, the strength of evidence favoring the SQ terbutaline pump over oral tocolytics or no treatment is low for the outcomes of incidence of delivery at <32 weeks and <37 weeks, and mean days of pregnancy prolongation. In women with RPTL and twin gestation, the strength of evidence favoring the pump over oral tocolytics is low for neonatal death, incidence of delivery at <32 weeks, and mean days of pregnancy prolongation. Strength of evidence is insufficient for bronchopulmonary dysplasia, incidence of delivery <28 weeks and <34 weeks, and withdrawals due to adverse events. Observational studies of medium to high risk of bias showed the benefit of the SQ terbutaline pump for other surrogate outcomes, such as birth weight and neonatal intensive care unit (NICU) admission. Absent or inconclusive evidence addressed all other neonatal health outcomes, neonatal harms, maternal harms, and pump-related outcomes. An assessment of confounding by maternal activity and maternal care was not possible due to sparse data. Until 2009, several cases of maternal deaths and maternal cardiovascular events in association with terbutaline tocolysis have been reported to the FDA. CONCLUSIONS: The evidence base consists of a small number of biased studies. A substantial body of evidence originated from one proprietary database. Although evidence suggests that pump therapy is beneficial as maintenance tocolysis, our confidence in its validity and reproducibility is low. While postmarketing surveillance has detected cases of serious harms, safety of the therapy remains unclear."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/1107750807> ;
   schema:genre "Meta-Analysis"@en ;
   schema:genre "National government publication"@en ;
   schema:genre "Evaluation Studies"@en ;
   schema:genre "Government publication"@en ;
   schema:genre "Tables"@en ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/1107750807#Series/comparative_effectiveness_review> ; # Comparative effectiveness review ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/1107750807#Series/ahrq_publication> ; # AHRQ publication ;
   schema:name "Terbutaline pump for the prevention of preterm birth"@en ;
   schema:productID "793411708" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/793411708#PublicationEvent/rockville_md_agency_for_healthcare_research_and_quality_2011> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/1107750807#Agent/agency_for_healthcare_research_and_quality> ; # Agency for Healthcare Research and Quality
   schema:url <http://www.ncbi.nlm.nih.gov/books/NBK82399/> ;
   schema:url <https://www.ncbi.nlm.nih.gov/books/NBK82399> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/793411708> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/1107750807#Agent/agency_for_healthcare_research_and_quality> # Agency for Healthcare Research and Quality
    a bgn:Agent ;
   schema:name "Agency for Healthcare Research and Quality" ;
    .

<http://experiment.worldcat.org/entity/work/data/1107750807#Series/ahrq_publication> # AHRQ publication ;
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/793411708> ; # Terbutaline pump for the prevention of preterm birth
   schema:name "AHRQ publication ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/1107750807#Series/comparative_effectiveness_review> # Comparative effectiveness review ;
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/793411708> ; # Terbutaline pump for the prevention of preterm birth
   schema:name "Comparative effectiveness review ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/1107750807#Topic/obstetric_labor_premature_prevention_&_control> # Obstetric Labor, Premature--prevention & control
    a schema:Intangible ;
   schema:name "Obstetric Labor, Premature--prevention & control"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1107750807#Topic/terbutaline_adverse_effects> # Terbutaline--adverse effects
    a schema:Intangible ;
   schema:name "Terbutaline--adverse effects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1107750807#Topic/terbutaline_therapeutic_use> # Terbutaline--therapeutic use
    a schema:Intangible ;
   schema:name "Terbutaline--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/1107750807#Topic/tocolytic_agents_therapeutic_use> # Tocolytic Agents--therapeutic use
    a schema:Intangible ;
   schema:name "Tocolytic Agents--therapeutic use"@en ;
    .

<http://viaf.org/viaf/129508251> # United States. Agency for Healthcare Research and Quality.
    a schema:Organization ;
   schema:name "United States. Agency for Healthcare Research and Quality." ;
    .

<http://viaf.org/viaf/250176625> # Laura Gaudet
    a schema:Person ;
   schema:familyName "Gaudet" ;
   schema:givenName "Laura" ;
   schema:name "Laura Gaudet" ;
    .

<http://viaf.org/viaf/5649149919442706650003> # University of Ottawa Evidence-based Practice Center.
    a schema:Organization ;
   schema:name "University of Ottawa Evidence-based Practice Center." ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.